JNJJanssen Research & Development, LLCRunning, no new patients
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
Multiple Myeloma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 208 (final count)
- Started
- Nov 7, 2019
- Main results expected
- Feb 26, 2027
- Fully finished
- Aug 25, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Cohorts A, B, C, D, E, and F: Percentage of Participants with Negative Minimal Residual Disease (MRD)
Measured over: At least 1 year after JNJ-68284528 infusion on Day 1
For US sites only: Cohort G: Percentage of Participants with Sustained MRD Negative Complete Response (CR)
Measured over: At least 1 year after JNJ-68284528 infusion on Day 1
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04133636 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC